Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) EBITDA (2016 - 2021)

Phio Pharmaceuticals' EBITDA history spans 10 years, with the latest figure at -$3.4 million for Q4 2021.

  • For Q4 2021, EBITDA fell 40.13% year-over-year to -$3.4 million; the TTM value through Dec 2021 reached -$13.5 million, down 53.66%, while the annual FY2024 figure was -$7.4 million, 31.75% up from the prior year.
  • EBITDA reached -$3.4 million in Q4 2021 per PHIO's latest filing, up from -$3.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.5 million in Q3 2018 to a low of -$7.1 million in Q1 2017.
  • Average EBITDA over 5 years is -$2.6 million, with a median of -$2.3 million recorded in 2020.
  • Peak YoY movement for EBITDA: crashed 215.41% in 2017, then surged 68.38% in 2018.
  • A 5-year view of EBITDA shows it stood at -$2.0 million in 2017, then rose by 12.91% to -$1.7 million in 2018, then tumbled by 53.92% to -$2.7 million in 2019, then rose by 7.76% to -$2.5 million in 2020, then plummeted by 40.13% to -$3.4 million in 2021.
  • Per Business Quant, the three most recent readings for PHIO's EBITDA are -$3.4 million (Q4 2021), -$3.7 million (Q3 2021), and -$2.7 million (Q2 2021).